Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

Cancer statistics, 2000

2000 • 3,907 citations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 • 2,777 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

2002 • 1,853 citations

Immune Inhibitory Receptors

2000 • 1,283 citations

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

1998 • 1,258 citations

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

2002 • 973 citations

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

1997 • 760 citations

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1984 • 714 citations

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

1997 • 698 citations

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

2000 • 695 citations

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

2002 • 660 citations

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

2000 • 576 citations

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

1998 • 576 citations

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

1997 • 531 citations

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

1998 • 527 citations

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

2001 • 521 citations

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

2002 • 430 citations

Evasion of innate immunity by parasitic protozoa

2002 • 429 citations

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

2001 • 425 citations

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

2000 • 388 citations

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

2003 • 384 citations

Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

2000 • 377 citations

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

2002 • 376 citations

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1999 • 369 citations

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas

2003 • 355 citations

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.

1993 • 349 citations

The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.

1985 • 232 citations

CD20‐mediated apoptosis: signalling through lipid rafts

2002 • 227 citations

Clustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent Apoptosis

2000 • 227 citations

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent mechanism

2002 • 225 citations

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

2001 • 220 citations

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

2001 • 211 citations

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

2001 • 209 citations

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone

2001 • 205 citations

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin

2001 • 193 citations

The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

1985 • 178 citations

Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?

2002 • 156 citations

Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment

1998 • 150 citations

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

1994 • 145 citations

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

2003 • 141 citations

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma

2002 • 139 citations

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid

2003 • 132 citations

Mice carrying a CD20 gene disruption

1998 • 129 citations

A UK multicentre phase II study of rituximab (chimaeric anti‐CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

2000 • 117 citations

Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review

2002 • 117 citations

Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis

2001 • 111 citations

Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20

1995 • 106 citations

Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2.

1993 • 100 citations

Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma

2001 • 89 citations

Colocalization of the B Cell Receptor and CD20 Followed by Activation-Dependent Dissociation in Distinct Lipid Rafts

2002 • 83 citations

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

2002 • 76 citations

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

2001 • 70 citations

Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

2002 • 69 citations

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils

2002 • 64 citations

Emerging information on the use of rituximab in chronic lymphocytic leukemia

2002 • 63 citations

Human Natural Killer Cell Receptors and Signal Transduction

2001 • 60 citations

Wintrobe's Clinical Hematology. Vol.1

1993 • 51 citations

CpG Oligodeoxynucleotides Enhance Monoclonal Antibody Therapy of a Murine Lymphoma

2000 • 42 citations

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

1997 • 24 citations

Weekly x 4 Induction Therapy with the Anti-CD20 Antibody Rituximab: Effect on Circulating t(14;18)+ Follicular Lymphoma Cells

2001 • 6 citations